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Objectives. To compare the effect of optimal medical treatment only (OMT) with OMT combined with percutaneous
transluminal angioplasty (OMTþ PTA) in patients with intermittent claudication (IC).
Design. A single centre prospective, randomised study. Quality of life (QoL) was the primary outcome measure. Secondary
measures were ankle-brachial-index (ABI), treadmill walking distances and mortality.
Methods. From a total of 434 patients considered for inclusion into the trial, only 56 patients with disabling IC fulfilled
the inclusion criteria. The patients were randomised into treatment groups consisting of 28 patients each and followed for
2 years. ABI and treadmill walking distances were measured in addition to the visual analogue scale (VAS) for pain eval-
uation, and QoL assessment using the Short Form (SF-36 and Claudication Scale (CLAU-S).
Results. The demographic data in the 2 groups were almost identical. After 2 years of follow-up the ABI, the treadmill
walking distances and the VAS were significant improved in the group treated with OMTþ PTA, compared to the group
treated with OMT only (p< 0.01 for all). Furthermore, some variables from the QoL assessment also showed a significant
improvement in favour of the OMTþ PTA group (p< 0.05 for all).
Conclusion. The advantage of conducting a single centre study and adhering to very strict inclusion criteria was illus-
trated by the homogenous demographic data of the two groups. This partly outweighed the disadvantage of having included
a relatively small number of patients. Early intervention with PTA in addition to OMT seems to have a generally more
positive effect compared to OMT only, on haemodynamic, functional as well as QoL aspects during the first 2 years in
patients with IC.
Keywords: Optimal medical treatment (OMT); Percutaneous transluminal angioplasty (PTA); Exercise training; Quality
of life (QoL); Treadmill walking distance.Introduction
Peripheral arterial occlusive disease (PAD) causing
intermittent claudication (IC) affects approximately
5% of the elderly population over 55 years.1 Local pro-
gression of disease occurs in approximately 25% and
about 1.6% end up with amputation.2,3 Annual mor-
tality rate in these patients is as high as 5e10%,
mainly caused by myocardial infarction and stroke.3,4
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Norway.
E-mail address: marthe@nylaende.com1078–5884/000003 + 10 $32.00/0  2006 Elsevier Ltd. All rights reseThere is still no cure for PAD. Hence, all treatment
of patients with IC should be minimally invasive and
aimed primarily at alleviating symptoms, eliminating
risk factors, and improving quality of life (QoL).5e9
First and foremost this is achieved by optimal medical
treatment (OMT), including patient education with
regard to exercise, nutrition and smoking cessation.
Medication include antiplatelet drugs as well as
lipid-lowering agents, antihypertensives, and antidia-
betic agents, when indicated.8,10e12
Percutaneous transluminal angioplasty (PTA) has
been popularised as a simple and effective treatment
with 5 year patency rates of 50e80%.13 It has been es-
timated that approximately 40% of patients with ICrved.
4 M. Nylænde et al.have arterial lesions amenable to PTA.14 As a result,
a large number of PTAs have been performed world
wide.
The effectiveness of OMT compared to PTA has not
yet been established, and it is still unclear whether
early intervention with PTA improves the QoL in
these patients. Only 2 prospective, randomised trials
comparing the effect of exercise training with PTA,
conducted in Oxford15,16 and in Edinburgh,16,18
respectively, fulfilled the criteria of the Cochrane
Review Group. However, these trials have also been
criticised for having several flaws, resulting in incon-
clusive findings.19
The aim of this single centre, prospective, rando-
mised study was to investigate whether patients
with IC are best treated with OMT only, or in combi-
nation with PTA. The primary outcome measure
was QoL. Secondary outcomes were ankle-brachial-
index (ABI), treadmill walking distances and mortal-
ity, evaluated after 3, 12 and 24 months.
Patient Screening (Fig. 1)
One surgeon only was responsible for the screening
process to secure optimal standardisation and adher-
ence to strict inclusion- and exclusion criteria.
Inclusion criteria:
 <80 years of age
 Symptomatic IC> 3 months
 ABI< 0.9 without pain at rest and/or ischemic
skin changes
 A lesion feasible for angioplasty evaluated by
angiography
 Subjective painfree walking distance
(PFWD)< 400 m
 Able to exercise on a treadmill
Exclusion criteria:
 Previous vascular or endovascular surgery
 Diabetic skin ulceration
 Renal insufficiency (defined as serum creatinine
>150 mmol/L)
 Oral anticoagulant medication, in order to mini-
mise the number of factors influencing the out-
come of treatment
 Suffering from a physical or mental disorder
expecting to impede compliance
During the 2-year inclusion period, 826 patients
were referred to the Oslo Centre of Vascular Surgery,
Aker University Hospital, Norway, with IC as tenta-
tive diagnosis. Based on the written information
from the referring general practitioners, only 434Eur J Vasc Endovasc Surg Vol 33, January 2007patients were invited to a consultation at our Outpa-
tient Department. The patient’s history was recorded
and a thorough clinical examination was performed,
including measurement of Doppler ABI, body-mass-
index (BMI) and CO-content in expired air. The Visual
Analogue Scale (VAS) was used to assess the patient’s
subjective maximum claudication pain. Furthermore,
information for the QoL questionnaires (Short Form
(SF-36) and Claudication Scale (CLAU-S)) was
recorded.
In this process 287 patients were excluded, 143 be-
cause of an incorrect clinical diagnosis by the referring
physicians (Fig. 1). Thus, the remaining 147 patients
underwent treadmill testing in order to get an objec-
tive measure of their painfree- and maximum walking
distance (PFWD and MWD, respectively). The tread-
mill test was performed twice. The first test was cho-
sen to familiarise the patients with the treadmill. The
second test was used in subsequent analyses, and was
performed later in the screening programme.
At this stage 16 patients were excluded, of whom
12 failed to exercise on the treadmill because of short-
ness of breath or feeling uncomfortable, 1 patient died
at home, and 3 refused to participate in the study.
Altogether, 131 patients managed to exercise on the
treadmill and were still willing to participate in the
Fig. 1. Flowchart of the patient selection from primary refer-
rals to randomisation and inclusion in the study.
5The 2-years Result of the OBACT-studystudy. They were hospitalised for 2 days for a final
screening. Fasting blood samples were drawn, and
the patients underwent their second test on the tread-
mill. In addition, all patients had a consultation with
a clinical nutritionist. Finally, the precise extent and
localisation of peripheral limb atherosclerosis was as-
sessed by angiography. Only patients with a lesion
feasible for PTA were included. At this stage another
75 patients were excluded for various reasons: 59
patients had lesions not amenable for PTA, 3 had de-
veloped diabetic ulcers, 2 had died and 11 were no
longer compliant (Fig. 1).
Finally, 56 patients could be included in the study.
Randomisation was performed in accordance with
a computerised randomisation list by use of consecu-
tively numbered sealed envelopes. Twenty-eight
patients were randomised to OMT and another 28 to
OMTþ PTA. Thus, the latter group was treated with
an additional angioplasty. The patients were followed
up for 2 years.
Approval was given from the Regional Ethical
Committee, and all patients gave their written, in-
formed consent to participate.
Patient follow-up
All patients were followed up at 3, 12 and 24 months.
Evaluation encompassed: ABI, PFWD, MWD, BMI,
fasting blood chemistry, VAS assessment, and the com-
pletion of the 2 QoL questionnaires. Smoking habits
were objectively evaluated by CO-measurements in
expired air. Compliance on exercise, nutrition and
medication were registered. The patients also had a con-
sultation with a clinical nutritionist twice during the 2
years of follow-up. Only 2 surgeons were involved in
the clinical and organisational part of the follow-up
program to secure a best possible compliance and
conformity of all procedures involved.
Methods
ABI measurement
After a 5 min rest period in the supine position,
a hand-held Doppler probe (Parks model 811, Parks
Medical Electronics Inc, Aloha, OR, USA), and
a 13 cm wide pneumatic cuff were used to measure
systolic blood pressures in the brachial artery, the an-
terior tibial artery and the posterior tibial artery in
both limbs.20 The highest mean of two consecutive
ankle pressure measurements in each artery was
used to calculate ABI. The ABI obtained from the
patient’s primary symptomatic side was used forsubsequent analysis. In the cases where the 2 sides
were symptomatically indiscriminate from one an-
other, the right leg was referred to as the primary
symptomatic leg.
Treadmill
A standard treadmill test (Treadmill Proform, Icon
Health & Fitness, Logan, USA) with a constant speed
of 3 km/h and a fixed grade of 10 was chosen. PFWD
and MWD were recorded. Walking was continued up
to a maximum of 600 m, (12 min, alternatively),
although some patients were able to walk further. In
these cases, the MWD was equaled to 600 m.
Angiographic score (Fig. 2)
All included patients underwent digital subtraction
angiography (DSA). We chose an angiographic scor-
ing system reflecting the over-all anatomical severity
of PAD.21 This would allow us to compare it with
the functional severity of PAD, as reflected by ABI,
treadmill walking distances and QoL findings. The
following arterial segments (distal aorta plus 10
segments on each side) were assessed: common iliac
artery, external iliac artery, common femoral artery,
profunda femoral artery, superficial femoral artery,
popliteal artery, tibio-peroneal trunk, anterior tibial
artery, posterior tibial artery and peroneal artery. A
score was given to the area with the greatest narrow-
ing in each segment. The following scores were used:
0¼ normal, 1¼ stenosis< 50% (luminal irregularities,
insignificant stenosis), 2¼ stenosis 50% (significant
stenosis), 3¼ occlusion. The different scores for each
of the 21 segments were then added up to give the
angiographic score for each patient, 63 being the
maximal score.
Visual analogue scale (VAS)
The VAS is frequently used to assess a patient’s per-
ception of pain, on which the patients rate their own
health between 0 and 10.22 The patients were asked
to rate their perception of leg pain in their primary
symptomatic leg just before they had to stop when
walking.
Quality of life assessment
The patients were asked to complete 2 questionnaires
assessing QoL. They were given the opportunity to
ask for assistance whenever necessary.Eur J Vasc Endovasc Surg Vol 33, January 2007
6 M. Nylænde et al.The SF-36 questionnaire is a generic instrument com-
prising 36 items and providing scores for 9 distinct
domains: physical functioning (PF), social functioning
(SF), vitality (V), role limitations due to physical (RP)
and emotional (RE) problems, mental health (MH),
bodily pain (BP), general health perception (HP) and
reported health transition (HT) rendering a profile of
health. Each domain was transformed into a 0e10
scale. The SF-36 is a useful and widely used QoL
instrument in patients with PAD.23,24
The CLAU-S has until recently been the most exten-
sively researched disease specific QoL questionnaire
for patients with IC. The questions are grouped into
5 domains, including 7 specific subgroups, which
each get a score: daily living, pain, social life,
Fig. 2. Schematic outline of the lower extremity arteries; da:
distal aorta, ci: common iliac artery, ei: external iliac artery,
cf: common femoral artery, pr: profunda femoral artery, sf:
superficial femoral artery, p: popliteal artery, tpt: tibial pero-
neal trunk, at: anterior tibial artery, pt: posterior tibial artery,
f: fibular artery.Eur J Vasc Endovasc Surg Vol 33, January 2007disease-specific anxiety and mood.25 Each domain
was transformed into a 0e10 scale.
Optimal medical treatment (OMT)
Since we still are not sure what the term ‘‘best medical
treatment’’ encompasses, we opted for the expression
of OMT, indicating a treatment based upon recent
information from the literature combined with the
best of our own resources to coach these patients.
All patients were thoroughly informed about how to
reduce the various risk factors for developing
atherosclerosis.5,6,10
Smokers were offered the use of nicotine plaster and
prescribed Zyban (bupropionhydrocloride), if not
contraindicated.26,27
Exercise training has been proven to have a positive
impact on IC and QoL.28 Our patients were offered
a home-based program, as it reflects the everyday
life to a larger degree than centre-based programs.29
They were informed about the importance of walking
and were explained how to organise their own private
exercise program by walking along the same path
twice a day and trying to steadily increase MWD.
Individual nutritional advice was given by a clinical
nutritionist at the time of randomisation and twice
during the follow-up period. A Mediterranean type
diet, rich in fruits, nuts, vegetables, fish, polyunsatu-
rated fatty acids and fibres was emphasised.30
Acetylsalicylic acid, 160 mg, daily, was prescribed to
all patients. The prophylactic effect of aspirin in pa-
tients with PAD, especially with regard to the preven-
tion of stroke and myocardial infarction, is well
documented.31 Patients with a previous history of
peptic ulcer received Plavix (clopidogrel).
Patients with untreated hypercholesterolaemia (defined
as s-total cholesterol> 5 mmol/L and/or s-LDL-
cholesterol> 3 mmol/L) had statins prescribed.32,33
According to general rules in Norway, the cheapest
generic medicine is prescribed preferably. Patients al-
ready using a certain statin on admission to the study
were permitted to continue with the particular agent
they used.
There is yet no convincing evidence that treatment
of hypertension reduces the progression of PAD, but
the association between hypertension and cerebral
stroke and myocardial infarction has been well docu-
mented.34 Hypertension is often defined as a systolic
blood pressure> 140 mmHg and/or diastolic pressure
> 90 mmHg.35 The treatment was individualised in
co-operation with the patient’s general practitioner,
based on relevant literature and generally accepted
practice.
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To measure the severity of stenosis the luminal diam-
eter at the site of narrowing was compared with the
vessel above and below the lesion.36 Lesions consid-
ered feasible for PTA were >50% stenoses or occlu-
sions of a length <8 cm. A balloon was chosen with
approximately the same diameter as the adjacent
normal appearing artery. In multi-level disease, both
iliac and infra-inguinal lesions were treated. Peak
systolic measurements were performed following iliac
angioplasty.
Angioplasty was considered to be successful if the
residual stenosis was < 30% and antegrade flow was
established. Iliac occlusions were treated with pri-
mary stenting. Iliac stenoses were selectively stented
if the result after PTA seemed unsatisfactory: residual
stenosis 30% or sluggish blood flow due to dissec-
tion or residual pressure gradient 10 mm Hg. The
appropriateness of this approach has been recently
documented.37
Stents were not used infra-inguinally. Although
there have been some reports on the beneficial use
of stents/stent grafts in the superficial femoral
arteries, our own experience does not confirm these
results, neither does the majority of previous publica-
tions.38 At the beginning of the procedure, patients
were given 5000 units of heparin intra-arterially.
Epidemiological and statistical considerations
The power estimation was based on the end-point
QoL under the following assumptions: We estimated
the improvement in the QoL in OMT group at 2 years
to be 20%. For group OMTþ PTA we estimated that
the improvement in QoL would be 40%. For a type-I
error of 5% and a power of 80% we would need
approximately 100 patients in each group, thus a total
of 200 patients.
The results of the QoL questionnaires were ana-
lysed by using Epi Info software version 3.3.2. The
other results were analysed using SPSS software pack-
age for Windows, version 12.0.1 (SPSS INC, Chicago,
Illinois, US). For group comparison of continuous
variables the Student’s t test was used when the distri-
bution was Gaussian with homogeneity of variance. If
not, the non-parametric Mann-Whitney test was used.
Categorical variables were assessed using the Chi-
square tables. When one of the expected values in
the cell was <5 under the null-hypothesis, the Yate’s
correction or the Fisher exact test was applied.To compare the changes between the 2 groups from
baseline to the end of a treatment period, we used the
Mann-Whitney test.
Results
Baseline data
Baseline demographic and laboratory data are pre-
sented in Table 1. Statistical analysis revealed no
significant difference between the 2 patient groups for
any of the recorded variables, except for antiplatelet
medication ( p¼ 0.022) before inclusion in the study.
The included patients had suffered from IC for
a median period of 14.5 months before inclusion,
Table 1. Demographic and laboratory data for groups OMT and
OMTD PTA. Proportions or median values (25, 75 percentiles)
are given
OMT (n¼ 28) OMTþ PTA
(n¼ 28)
Male n (%) 15 (54) 16 (57)
Age (years) 69 (61,75) 68 (56,72)
SBP mmHg 153 (140,170) 153 (136,170)
DBP mmHg 80 (70,85) 80 (74,85)
Unilateral symptoms n (%) 18 (64) 17 (61)
Duration of symptoms of IC
(months)
12 (5,48) 17 (6,36)
ABI symptomatic leg 0.65 (0.52,0.74) 0.63 (0.56,0.71)
ABI contralateral leg 0.93 (0.78,1.12) 0.93 (0.77,1.02)
Angiographic score (0e63) 13 (10,23) 13 (6,18)
VAS score 6.2 (5.0,7.5) 6.4 (5.0,7.4)
PFWD on treadmill (0e600 m) 47 (33,81) 62 (35,83)
MWD on treadmill (0e600 m) 224 (137,517) 190 (101,591)
Subjective PFWD (m) 150 (50,275) 150 (100,200)
Subjective MWD (m) 325 (200,475) 300 (200,600)
Treated hypertension n (%) 15 (54) 8 (29)
Treatment with
antiplateletsa,b n (%)
13 (46) 5 (18)
Treated hypercholesterolemia
n (%)
6 (21) 8 (29)
Untreated hypercholesterolemia
n (%)
20 (71) 16 (57)
Diabetes mellitus (Type I and II)
n (%)
6 (21) 4 (14)
COLD n (%) 2 (7) 2 (7)
CHD n (%) 5 (18) 2 (7)
Smokers (current/previous)
n (%)
19 (68)/8 (29) 20 (71)/6 (21)
Smoking years 42 (36,50) 42 (33,50)
BMI kg/m2 25 (23,26) 26 (23,28)
s-LDL mmol/L 3.7 (3.2,4.5) 3.4 (2.7,4.2)
s-HDL mmol/L 1.36 (1.12,1.68) 1.35 (1.16,1.58)
s-Total Cholesterol mmol/L 5.6 (5.0,6.5) 5.7 (4.9,6.4)
s-triglycerides mmol/L 1.3 (0.93,1.60) 1.5 (1.1,1.9)
b-HbA1c % 6.2 (5.6,6.7) 6.0 (5.8,6.3)
s-glucose mmol/L 5.7 (5.3,6.9) 5.7 (5.2,6.1)
SBP: systolic brachial pressure, DBP: diastolic brachial pressure,
COLD: chronic obstructive lung disease, BMI: body-mass-index,
CHD: coronary heart disease. For other abbreviations: see text.
a aspirin or clopidogrel.
b p¼ 0.022 for difference between groups.Eur J Vasc Endovasc Surg Vol 33, January 2007
8 M. Nylænde et al.and their median perception of claudication pain as
assessed by VAS was 6.3. Seventy % of the patients
were current smokers, 25% had smoked previously,
and only 5% had never been smokers. Sixty-four %
had untreated hypercholesterolaemia, and 18% had
diabetes mellitus. Coronary heart disease was defined
as a known previous myocardial infarction and/or
angina pectoris and was recorded in 13% of the
patients.
Details on location of main obstructions and limb
involvement are shown in Table 2. There were no
significant group differences. The angioplasty was
technically successful in all 28 cases in group
OMTþ PTA. No significant complications were
encountered, such as bleeding, local thrombosis,
emboli, local arterial dissection or perforation. A few
patients had a small haematoma in the groin, but
none was in need of surgical revision.
Statistical analysis revealed no significant differ-
ences between the recorded QoL-measurements be-
tween the 2 groups at baseline.
Results at follow-up
Compliance to attendance was practically identical in
the 2 groups (Table 3). The numbers of patients who
died or were lost during the follow-up period were
not significantly different between the 2 groups. Two
patients crossed-over from the OMT to the OMTþ
PTA group, and were thus treated with PTA.
There was no difference in compliance to OMT be-
tween the 2 groups with regard to smoking cessation,
exercise training, diet, or use of medication such as
statins, antiplatelets, antihypertensives and antidia-
betic agents.
No group differences were recorded in ABI at base-
line. After 24 months ABI in group OMT remained
unchanged, whereas it had increased significantly af-
ter 3 months and was sustained throughout the study
in the OMTþ PTA group (Table 4). The differences in
change between the two groups were highly statisti-
cally significant ( p< 0.001 for all).
At the beginning of the study PFWD and MWD
were not different between the groups (Table 4). After
Table 2. Angiographical peripheral arterial obstruction. Location
and limb involvement. Proportions are given
Site Total population (n¼ 56)
Unilateral Bilateral
Aortoiliac n (%) 1 (1.8) 9 (16.1)
Femoropopliteal n (%) 0 1 (1.8)
Combined n (%) 0 45 (80.4)
Total n (%) 1 (1.8) 55 (98.2)Eur J Vasc Endovasc Surg Vol 33, January 20073, 12 and 24 months, these variables had increased sig-
nificantly in both groups, though significantly more in
the OMTþ PTA group, compared to the OMT group
( p< 0.05 for all).
After 3 months the VAS-score was significantly
more reduced in the OMTþ PTA group, compared
to the OMT group ( p< 0.0001) (Table 4). This positive
effect lasted almost unchanged during the whole
follow-up period. In the OMT alone group the VAS-
score also decreased significantly over time.
We obtained information from 9 domains of the
SF-36 and compared the results of the 2 groups at
the start of the study and after 3, 12 and 24 months
(Table 5). The measured differences in changes from
baseline were statistically significant in favour of the
OMTþ PTA group. The greatest difference between
the groups was obtained after 3 months in the do-
mains of physical functioning ( p¼ 0.0003), bodily
pain ( p< 0.014), and reported health transition
( p< 0.0001). Only with regard to physical functioning
did this positive effect last for 2 years ( p< 0.0098).
Within both groups the reported health transition
were improved at 12 and 24 weeks ( p< 0.001 for all).
The most noticeable differences in QoL between the
groups were shown in the results from the CLAU-S
form (Table 6). In 2 of the 7 domains, pain during
activity and pain severity, respectively, the group
OMTþ PTA had improved significantly at 3 and 12
months, compared to the OMT group ( p< 0.05)
(Table 6). However, after 2 years no differences
between groups were recorded.
Discussion
Life-style modification and relevant medication is
still the cornerstone in treating patients with PAD.39
However, millions of PTAs have been performed
world-wide, without its potential additive effect hav-
ing been fully evaluated. The research question for the
OBACT study was whether OMT only or in combination
with early PTA is the best treatment for patients with IC.
We opted for a single centre study to obtain the best
Table 3. Compliance to attendance for group 1: OMT and group
2: OMTD PTA
Number of patients included Group Number of patients 56
Lost to follow-up 1 4 5
2 1
Cross-over 1 2 2
2 0
Dead 1 0 1
2 1
Patients at end of study 48
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guidance of the patients and follow-up.
The primary end-point was QoL because all treat-
ment of patients with IC focuses on increasing QoL,
as well as preventing death caused by myocardial in-
farction or stroke. IC can be very disabling as patients
are prohibited from carrying out their daily activities.
Thus, health-related QoL scores are reportedly much
lower in patients with IC than in age-matched groups
without clinical symptoms of PAD.40
Screening/selection of patients
It was interesting to note that 33% of the referred pa-
tients had symptoms incorrectly diagnosed as IC. In
addition, 6% of the patients had developed critical
ischemia by the time they were examined at the
Outpatients’ clinic. These findings made us distribute
up-dated information to general practitioners on how
to examine, treat and refer patients with PAD.
Sixteen patients were excluded because they did
not manage to walk on the treadmill. They were
elderly, had difficulties with keeping their balance or
complained of shortness of breath. Forty-five % of
the patients had to be excluded because the arterial le-
sions were not amenable for PTA. This finding agrees
with our own previous experience as well as the expe-
rience of other centres.41
Although the Oxford and Edinburgh studies had
less strict inclusion/exclusion criteria than our study,
they experienced similar problems in including pa-
tients.15e18 Thus, neither the Edinburgh, nor the
Oxford study had an upper age limit for participation.
The Oxford study accepted patients earlier treated
with endovascular and/or vascular surgery and tak-
ing oral anticoagulants. Furthermore, the Edinburgh
study included patients with duration of symptomatic
IC> 1 month, whereas the Oxford study had a mini-
mum duration of symptomatic IC of 3 months, similar
to the OBACT study.
It may seem controversial that we only included
patients with a subjective PWD <400 m. However,
this reflects the everyday vascular practice in Norway.
All patients with IC primarily undergo a 4e6 months
standard regimen of OMT, and after this period they
are evaluated for a possible PTA.
The strict entry criteria while limited the numbers
of patients included did result in homogenous groups
of patients with good compliance to the follow-up
(Table 3). It should also be emphasized that the results
presented have been obtained in patients with PFWD
<400 m and angiographically verification of lesion (s)
feasible for PTA. The results are therefore not easily
10 M. Nylænde et al.Table 5. Results of the SF-36 questionnaire
Subgroups Treatment Baseline 3 months 12 months 24 months
Physical functioning 1 NS 0.33 (0.12)* p¼ 0.0003 NS 0.11 (0.32) p¼ 0.0098
2 0.16 (0.02)*** 0.06 (0.26)
Physical role 1 NS NS NS NS
2
Bodily pain 1 NS 0.03 (0.25) p¼ 0.014 *** NS NS
2 0.07 (0.20) ***
General health 1 NS NS NS NS
2
Vitality 1 NS NS NS NS
2
Social functioning 1 NS NS NS NS
2
Role emotional 1 NS NS NS 0.15 (0.33) p¼ 0.0372
2 0.02 (0.34)
Mental health 1 NS NS NS NS
2
Reported health transition 1 NS 0.16 (0.50) p< 0.0001 ** NS *** NS
2 0.60 (0.26)*** *** ***
Group 1: OMT. Group 2: OMTþ PTA. NS: Not significant. Mean and standard deviation is calculated as difference of score between actual
month and start of study. P-values represent inter-group difference in changes. *p< 0.05, **p< 0.001, ***p< 0.0001 represent intra-group
changes from baseline.generalized to the common IC patient in everyday
practise.
Baseline data
Angiography is still considered the gold standard in
presenting anatomical information of the arteries,
whereas ABI represents the physiology. The patients’
perception of maximum walking pain, determinedEur J Vasc Endovasc Surg Vol 33, January 2007by the VAS, shows median values of 6.2 and 6.4 for
group OMT and group OMTþ PTA, respectively.
This finding is in accordance with the fact that these
patients experienced pain when walking at the time
of the inclusion. The primary technical results of
PTA where similar to those from the literature, where
more than 90% of femoral stenoses and short occlu-
sions can be successfully dilated in experienced
hands.42Table 6. Results of CLAU-S questionnaire
Subgroups Treatment Baseline 3 months 12 months 24 months
Every day life 1 NS NS 0.01 (0.25) p¼ 0.0334 NS
2 0.12 (0.17)
Pain during activity 1 NS 0.04 (0.17) p¼ 0.0014 0.06 (0.28) p¼ 0.0381 * NS
2 0.20 (0.19)*** 0.19 (0.21)*** ***
Severity of pain 1 NS 0.03 (0.09) p¼ 0.0010 0.16 (0.24)** p¼ 0.0085 NS
2 0.10 (0.08)*** 0.02 (þ0.22)
Pain related
to sleep
1 NS NS NS NS
2
Social life 1 NS NS NS NS
2
Specific fears
rel. to illness
1 NS NS NS NS
2
Psychological well-being 1 NS NS NS NS
2
Group 1: OMT. Group 2: OMTþ PTA. NS: Not significant. Mean and standard deviation is calculated as difference of score between actual
month and baseline. P-values represent inter-group difference in changes. *p< 0.05 represents intra-group changes from baseline.
11The 2-years Result of the OBACT-studyIntervention results
Physical and functioning measurements
It was not surprising that ABI increased immediately
after PTA, but we did not expect this result to be
maintained for as long as 2 years. The benefit of
PTA, expressed by the ABI findings, is definitely
more significant in our study compared to the Oxford
and Edinburgh studies,15e18 possibly due to our strict
inclusion/exclusion criteria and the much standar-
dised follow-up programme.
The improvement of PFWD as well as MWD in
both groups clearly illustrates the advantage of
intervention with OMT, which was received by
both groups, although the increase in treadmill walk-
ing distances was significantly larger in the
OMTþ PTA group. The significant additional effect
of PTA on the patient’s walking ability appeared
after 3 months, as might be expected, and lasted
for at least 2 years.
Regarding the VAS-score, the beneficial effect of
performing additional PTA was very convincing,
and the effect lasted almost unchanged during the 2
years. The patients in the OMT group never achieved
the improvement seen with the OMTþ PTA group.
This supports the results from a recent study compar-
ing the effect of exercise training with PTA.43
Even though the ABI, the treadmill walking dis-
tances and the VAS were improved in favour of the
OMTþ PTA group during the 2 years of follow-up,
significant improvement over time was also obtained
in the OMT only group. This demonstrates that OMT
in itself is a beneficial treatment option for patients
suffering from IC, and whose arterial lesions are not
amenable for PTA.
QoL-measurements
The information from the SF-36 evaluation, does not
allow us to make definite conclusions on the effect
of OMT versus OMTþ PTA on the QoL in patients
with IC. The results have to be interpreted with cau-
tion as the number of patients entered was signifi-
cantly less than required in the power calculation.
However, the significant differences reflected in 3 of
the 9 domains, physical functioning, bodily pain and
reported general health, respectively, were all in fa-
vour of the OMTþ PTA group. This positive effect
started early, which is in accordance with the findings
of early improvement of ABI and treadmill walking
distances in these patients.
The most obvious differences in QoL between the
groups were obtained from the CLAU-S forms. In
2 of the 7 domains, pain during activity and pain
severity, respectively, the OMTþ PTA group didsignificantly better after 3 and 12 months, compared
to the OMT group. However, these differences were
not sustained at 2 years.
It has been stated that the generic SF-36 assessment
is too little disease specific. Nevertheless, a recent pro-
spective (but non-randomised) study comparing the
effect of PTA (47 patients) with OMT (23 patients),
also showed the very beneficial effect of PTA with
regard to ABI, treadmill walking distances, VAS and
QoL.24 The authors of this study, comparing different
forms of QoL assessment, concluded that future
research analysing QoL in claudicants should include
the generic SF-36 and the recently developed disease-
specific VascuQol.24
In our primary power estimation we used 20% dif-
ference in change of QoL between the 2 arms of the
trial after 2 years, which means 100 patients in each
arm were required. Unfortunately, fewer patients
than expected were included. The inclusion was
stopped after 2 years, even though we had only man-
aged to include 56 of the 200 patients required for the
evaluation of QoL, the study’s primary end-point.
We realized that in order to include 200 patients we
would probably need to include patients for another
6e8 years. To evaluate the secondary end-points of
the study, however, the number obtained was esti-
mated to be sufficient. Hence, our study seems to
have enough power with regard to the the evaluation
of the ABI, the treadmill walking distances and the VAS.
In conclusion, our findings support a benefit of
PTA in improving outcome for IC. Our secondary
endpoints, ABI, treadmill walking distances and
VAS all definitely confirm the beneficial effect of per-
forming PTA, sustaining for at least 2 years.
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